Stockholm, 2014-12-22 11:54 CET (GLOBE NEWSWIRE) --
The first surgery has been performed with Episealer Knee Trochlea, the second commercial product of Episurf Medical. Episealer® Knee Trochlea is intended to treat cartilage defects in the area behind the patella (kneecap). The surgery was carried out by Professor Peter Verdonk from AZ Monica Hospital in Belgium. The patient was a 47 year old male with knee pain despite previous inventions.
"It is known that biological treatment solutions are less effective for middle aged patients, which means that Episurf's personalized implants can fill a need for this group of patients. The implant fitted perfectly in the damaged area and could be placed with excellent precision. The surgery also took less time because patient specific instruments were used instead of standard instruments. This individualised approach enables me to customize the surgery to the patient’s anatomy and optimise the implant positioning", commented Professor Peter Verdonk from AZ Monica Hospital.
"Professor Verdonk is one of the most recognized orthopedic surgeons in Europe and we are delighted that he has chosen to use Episurf's implant for a patient who previously lacked adequate treatment options. The patients we target are often active people of working age who only have been offered painkillers and sick leave to ease their discomfort. By using Episurf's personalized implant, we can not only save patients long-term pain and suffering, we can also achieve substantial savings for the society in terms of reduced sick leave", commented Nina Bake, CEO of Episurf Medical.
Episealer®Knee Trochlea secured European marketing approval in the form of CE-certification in October 2014 and is since then offered to selected clinics in Europe via a controlled product launch (CPL). The company's first product, the personalized implant Episealer® Femoral Condyle, has been in a CPL since the fall of 2013.
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system will enable implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act. For more information, go to the company’s website: www.episurf.com
For more information, please contact:
Nina Bake, CEO of Episurf Medical AB (publ)
Tel: +46 (0)73 612 5563, e-mail: ir@episurf.com
